SEPTInvestingStart Free

LYEL SCHEDULE 13G/A: SEC filing

ARCH Venture Fund entities and affiliated individuals

Filed with the SEC on · accession 0001012975-26-001025

LYEL filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 10, 2026. A report the company filed with the SEC (the US market regulator). The stock moved +8.6% by the first close after the filing.

Summary of the filing

ARCH Venture Fund entities and affiliated individuals filed an amended Schedule 13G reporting beneficial ownership of approximately 17.4% of Lyell Immunopharma's common stock, with the filing noting the issuer sold 7,428,040 shares in a private placement on November 4, 2026.

For details, click here →

Key details

Shares of common stock beneficially owned by ARCH Venture Fund entities$5.6M
Shares of common stock sold by Lyell in private placement on November 4, 2026$7.4M
Shares of common stock outstanding as of October 30, 2026$24.6M
IssuerLyell Immunopharma, Inc.
Reporting person / beneficial ownerARCH Venture Fund IX, L.P.
Reporting person / beneficial ownerARCH Venture Fund IX Overage, L.P.
Reporting person / beneficial ownerARCH Venture Fund XIII, L.P.
Reporting person / general partnerARCH Venture Partners IX, L.P.
Reporting person / general partnerARCH Venture Partners IX Overage, L.P.
Reporting person / general partnerARCH Venture Partners IX, LLC
Reporting person / general partnerARCH Venture Partners XIII, L.P.
Reporting person / general partnerARCH Venture Partners XIII, LLC
Managing director, arch venture partnersKeith Crandell
Managing director, arch venture partnersRobert Nelsen
Investment committee member, arch venture partnersKristina Burow
Investment committee member, arch venture partnersSteven Gillis
Managing director, arch venture partnersClinton Bybee
Investment committee member, arch venture partnersPaul Berns

How LYEL stock reacted

Close before

$15.42

Nov 9, 2026

First close after

+8.63%

$16.75

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for LYEL, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for LYEL?

Click here

Frequently asked questions

What did LYEL file with the SEC on Nov 10, 2026?

LYEL filed a SCHEDULE 13G/A (SEC filing). ARCH Venture Fund entities and affiliated individuals filed an amended Schedule 13G reporting beneficial ownership of approximately 17.4% of Lyell Immunopharma's common stock, with the filing noting the issuer sold 7,428,040 shares in a private placement on November 4, 2026.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did LYEL stock react to this filing?

LYEL closed at $15.42 before the filing and $16.75 on Nov 10, 2026 (+8.63%).

Other LYEL SEC filings

Get alerts when LYEL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
LYEL overviewLYEL analysisLYEL newsLatest SEC filings